AI-aided design of novel targeted covalent inhibitors against SARS-CoV-2

The focused drug repurposing of known approved drugs (such as lopinavir/ritonavir) has been reported failed for curing SARS-CoV-2 infected patients. It is urgent to generate new chemical entities against this virus. As a key enzyme in the life-cycle of coronavirus, the 3C-like main protease (3CLpro or Mpro) is the most attractive for antiviral drug design. Based on a recently solved structure (PDB ID: 6LU7), we developed a novel advanced deep Q-learning network with the fragment-based drug design (ADQN-FBDD) for generating potential lead compounds targeting SARS-CoV-2 3CLpro. We obtained a series of derivatives from those lead compounds by our structure-based optimization policy (SBOP). All the 47 lead compounds directly from our AI-model and related derivatives based on SBOP are accessible in our molecular library at https://github.com/tbwxmu/2019-nCov. These compounds can be used as potential candidates for researchers in their development of drugs against SARS-CoV-2.

[1]  K. Gajiwala,et al.  Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19 , 2020, Journal of medicinal chemistry.

[2]  Igor V. Tetko,et al.  Transformer-CNN: Swiss knife for QSAR modeling and interpretation , 2020, Journal of Cheminformatics.

[3]  Hualiang Jiang,et al.  Structure of Mpro from COVID-19 virus and discovery of its inhibitors , 2020, bioRxiv.

[4]  Zhen Wu,et al.  A self-attention based message passing neural network for predicting molecular lipophilicity and aqueous solubility , 2020, Journal of Cheminformatics.

[5]  Xiu-Jie Wang,et al.  Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines , 2020, Journal of Genetics and Genomics.

[6]  R. Hilgenfeld,et al.  α-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment , 2020, Journal of medicinal chemistry.

[7]  Christian Drosten,et al.  Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the Coronavirus Study Group , 2020, bioRxiv.

[8]  W Patrick Walters,et al.  Assessing the impact of generative AI on medicinal chemistry , 2020, Nature Biotechnology.

[9]  Xiu-Jie Wang,et al.  Potential inhibitors for 2019-nCoV coronavirus M protease from clinically approved medicines , 2020, bioRxiv.

[10]  Francesca Grisoni,et al.  Bidirectional Molecule Generation with Recurrent Neural Networks , 2020, J. Chem. Inf. Model..

[11]  Rede de Informação e Conhecimento.  Coronavirus COVID-19 Global Cases by Johns Hopkins CSSE , 2020 .

[12]  Alán Aspuru-Guzik,et al.  Deep learning enables rapid identification of potent DDR1 kinase inhibitors , 2019, Nature Biotechnology.

[13]  Shuang Wang,et al.  Molecule Property Prediction Based on Spatial Graph Embedding , 2019, J. Chem. Inf. Model..

[14]  G. Schneider,et al.  Concepts of Artificial Intelligence for Computer-Assisted Drug Discovery. , 2019, Chemical reviews.

[15]  Lei Jia,et al.  Chemi-Net: A Molecular Graph Convolutional Network for Accurate Drug Property Prediction , 2018, International journal of molecular sciences.

[16]  M. Scharf,et al.  Rapid evolutionary responses to insecticide resistance management interventions by the German cockroach (Blattella germanica L.) , 2019, Scientific Reports.

[17]  Zois Boukouvalas,et al.  Deep learning for molecular generation and optimization - a review of the state of the art , 2019, Molecular Systems Design & Engineering.

[18]  Li Li,et al.  Optimization of Molecules via Deep Reinforcement Learning , 2018, Scientific Reports.

[19]  Alejandro Speck-Planche,et al.  Recent advances in fragment-based computational drug design: tackling simultaneous targets/biological effects. , 2018, Future medicinal chemistry.

[20]  Jure Leskovec,et al.  Graph Convolutional Policy Network for Goal-Directed Molecular Graph Generation , 2018, NeurIPS.

[21]  W. Fast,et al.  The Taxonomy of Covalent Inhibitors. , 2018, Biochemistry.

[22]  Regina Barzilay,et al.  Junction Tree Variational Autoencoder for Molecular Graph Generation , 2018, ICML.

[23]  Olexandr Isayev,et al.  Deep reinforcement learning for de novo drug design , 2017, Science Advances.

[24]  Joseph Gomes,et al.  MoleculeNet: a benchmark for molecular machine learning† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c7sc02664a , 2017, Chemical science.

[25]  Fernanda Borges,et al.  Chromone as a Privileged Scaffold in Drug Discovery: Recent Advances. , 2017, Journal of medicinal chemistry.

[26]  Alán Aspuru-Guzik,et al.  Objective-Reinforced Generative Adversarial Networks (ORGAN) for Sequence Generation Models , 2017, ArXiv.

[27]  Thomas Blaschke,et al.  Molecular de-novo design through deep reinforcement learning , 2017, Journal of Cheminformatics.

[28]  Vijay S. Pande,et al.  MoleculeNet: a benchmark for molecular machine learning , 2017, Chemical science.

[29]  Jiun-Jie Shie,et al.  Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CLPro inhibitors , 2017, Antiviral Research.

[30]  Wojciech Zaremba,et al.  OpenAI Gym , 2016, ArXiv.

[31]  Y. Hayashi,et al.  An Overview of Severe Acute Respiratory Syndrome–Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy , 2016, Journal of medicinal chemistry.

[32]  Tom Schaul,et al.  Dueling Network Architectures for Deep Reinforcement Learning , 2015, ICML.

[33]  Tom Schaul,et al.  Prioritized Experience Replay , 2015, ICLR.

[34]  David Silver,et al.  Deep Reinforcement Learning with Double Q-Learning , 2015, AAAI.

[35]  Kai Zhu,et al.  Docking Covalent Inhibitors: A Parameter Free Approach To Pose Prediction and Scoring , 2014, J. Chem. Inf. Model..

[36]  C. Lindsley,et al.  Discovery of N-(benzo[1,2,3]triazol-1-yl)-N-(benzyl)acetamido)phenyl) carboxamides as severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro inhibitors: Identification of ML300 and noncovalent nanomolar inhibitors with an induced-fit binding , 2013, Bioorganic & Medicinal Chemistry Letters.

[37]  E. Freire,et al.  Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: Design, synthesis, biological evaluation, and docking studies , 2013, European Journal of Medicinal Chemistry.

[38]  Z. Rao,et al.  The newly emerged SARS-Like coronavirus HCoV-EMC also has an “Achilles’ heel”: current effective inhibitor targeting a 3C-like protease , 2013, Protein & Cell.

[39]  C. Lindsley,et al.  Discovery, synthesis, and structure-based optimization of a series of N-(tert-butyl)-2-(N-arylamido)-2-(pyridin-3-yl) acetamides (ML188) as potent noncovalent small molecule inhibitors of the severe acute respiratory syndrome coronavirus (SARS-CoV) 3CL protease. , 2013, Journal of medicinal chemistry.

[40]  G. V. Paolini,et al.  Quantifying the chemical beauty of drugs. , 2012, Nature chemistry.

[41]  M. Kusunoki,et al.  Structure-based design, synthesis, and evaluation of peptide-mimetic SARS 3CL protease inhibitors. , 2011, Journal of medicinal chemistry.

[42]  Peter Ertl,et al.  Mining for Bioactive Scaffolds with Scaffold Networks: Improved Compound Set Enrichment from Primary Screening Data , 2011, J. Chem. Inf. Model..

[43]  Adrian Whitty,et al.  The resurgence of covalent drugs , 2011, Nature Reviews Drug Discovery.

[44]  P. Liang,et al.  Synthesis and evaluation of pyrazolone compounds as SARS-coronavirus 3C-like protease inhibitors , 2010, Bioorganic & Medicinal Chemistry.

[45]  K. Park,et al.  Biflavonoids from Torreya nucifera displaying SARS-CoV 3CLpro inhibition , 2010, Bioorganic & Medicinal Chemistry.

[46]  P. Liang,et al.  Individual and common inhibitors of coronavirus and picornavirus main proteases , 2009, FEBS Letters.

[47]  Matthias Rarey,et al.  On the Art of Compiling and Using 'Drug‐Like' Chemical Fragment Spaces , 2008, ChemMedChem.

[48]  Debbie C. Mulhearn,et al.  Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors , 2008, Bioorganic & Medicinal Chemistry Letters.

[49]  H. Saito,et al.  Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant , 2008, Bioorganic & Medicinal Chemistry.

[50]  A. Yang,et al.  Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease , 2008, Bioorganic & Medicinal Chemistry.

[51]  Stefan Wetzel,et al.  The Scaffold Tree - Visualization of the Scaffold Universe by Hierarchical Scaffold Classification , 2007, J. Chem. Inf. Model..

[52]  Matthew P. Repasky,et al.  Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. , 2006, Journal of medicinal chemistry.

[53]  Po-Huang Liang,et al.  Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease. , 2006, Journal of medicinal chemistry.

[54]  Thy-Hou Lin,et al.  Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies. , 2006, Journal of medicinal chemistry.

[55]  Jörg Rademann,et al.  An Efficient Method for the Synthesis of Peptide Aldehyde Libraries Employed in the Discovery of Reversible SARS Coronavirus Main Protease (SARS‐CoV Mpro) Inhibitors , 2006, Chembiochem : a European journal of chemical biology.

[56]  Chi‐Huey Wong,et al.  Stable Benzotriazole Esters as Mechanism-Based Inactivators of the Severe Acute Respiratory Syndrome 3CL Protease , 2006, Chemistry & Biology.

[57]  K. Yuen,et al.  Correction: Design of Wide-Spectrum Inhibitors Targeting Coronavirus Main Proteases , 2005, PLoS biology.

[58]  Arun K. Ghosh,et al.  Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors. , 2005, Journal of medicinal chemistry.

[59]  K. Yuen,et al.  Correction: Design of Wide-Spectrum Inhibitors Targeting Coronavirus Main Proteases , 2005, PLoS Biology.

[60]  Chi‐Huey Wong,et al.  Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic α,β-unsaturated esters , 2005, Bioorganic & Medicinal Chemistry.

[61]  Chi‐Huey Wong,et al.  Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease. , 2005, Journal of medicinal chemistry.

[62]  J. Vederas,et al.  Synthesis and evaluation of keto-glutamine analogues as potent inhibitors of severe acute respiratory syndrome 3CLpro. , 2004, Journal of medicinal chemistry.

[63]  Hsuan-Cheng Huang,et al.  Small molecules targeting severe acute respiratory syndrome human coronavirus. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[64]  Philip Picton,et al.  Concepts in artificial intelligence , 1994 .